Effects of M-1, a Major Metabolite of Sarpogrelate, on 5-HT-Induced Constriction of Isolated Human Internal Thoracic Artery-Reference-Cited by-同舟云学术

Effects of M-1, a Major Metabolite of Sarpogrelate, on 5-HT-Induced Constriction of Isolated Human Internal Thoracic Artery

Published:2020-12-01 Issue:12 Volume:43 Page:1979-1982
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Tanaka-Totoribe Naoko¹,Hidaka Muneaki¹,Gamoh Shuji¹,Yokota Atsuko²,Nakamura Eisaku³,Kuwabara Masachika⁴,Tsunezumi Jun¹,Yamamoto Ryuichi¹

Affiliation:

1. Graduate School of Clinical Pharmacy, Kyushu University of Health and Welfare

2. Department of Cardiovascular Surgery, Miyazaki City Medical Association Hospital

3. Department of Cardiovascular Surgery, Miyazaki Prefectural Miyazaki Hospital

4. Kuwabara Clinic

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/43/12/43_b20-00591/_pdf

Reference30 articles.

1. 1) Kroeze WK, Kristiansen K, Roth BL. Molecular biology of serotonin receptors structure and function at the molecular level. Curr. Top. Med. Chem., 2, 507–528 (2002).

2. 2) Nagatomo T, Rashid M, Abul Muntasir H, Komiyama T. Functions of 5-HT_2A receptor and its antagonists in the cardiovascular system. Pharmacol. Ther., 104, 59–81 (2004).

3. 3) Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev., 46, 157–203 (1994).

4. 4) Gamoh S, Hisa H, Yamamoto R. 5-Hydroxytryptamine receptors as targets for drug therapies of vascular-related diseases. Biol. Pharm. Bull., 36, 1410–1415 (2013).

5. 5) Vanhoutte PM. Endothelial dysfunction and vascular disease. Verh. K. Acad. Geneeskd. Belg., 60, 251–266 (1998).

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Selective Serotonin 2A Receptor Antagonist Sarpogrelate Prevents Cardiac Hypertrophy and Systolic Dysfunction via Inhibition of the ERK1/2–GATA4 Signaling Pathway;Pharmaceuticals;2021-12-05